NasdaqGS:MGNXBiotechs
MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses
MacroGenics stock ticked up 3.4% to US$4.22 into the weekend, a modest relief move for a biotech that has been grinding through loss-making quarters and a choppy three month stretch. The headline from this earnings release is not the top line; it is the size of the earnings drag. MacroGenics reported a quarterly loss of US$69.6 million from ongoing operations and basic earnings per share of US$1.10 in the red. For anyone thinking beyond today’s small bounce, the real question is how long this...